## Frederik Hendrik Verbrugge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7468069/publications.pdf

Version: 2024-02-01

142 papers 4,389 citations

94433 37 h-index 61 g-index

154 all docs

154 docs citations

154 times ranked

4362 citing authors

#	Article	IF	Citations
1	Cardiopulmonary Exercise Testing with Echocardiography to Identify Mechanisms of Unexplained Dyspnea. Journal of Cardiovascular Translational Research, 2022, 15, 116-130.	2.4	12
2	Mitral Annular Dynamics in AF VersusÂSinus Rhythm. JACC: Cardiovascular Imaging, 2022, 15, 1-13.	5.3	18
3	Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annual Review of Medicine, 2022, 73, 321-337.	12.2	52
4	Identification of patients with preclinical heart failure with preserved ejection fraction using the H2FPEF score. , 2022, 1, 59-66.		6
5	Detection of Left Atrial Myopathy Using Artificial Intelligence–Enabled Electrocardiography. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE120008176.	3.9	10
6	Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. European Heart Journal, 2022, 43, 1941-1951.	2.2	68
7	Exercise Systolic Reserve and Exercise Pulmonary Hypertension Improve Diagnosis of Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2022, 9, 814601.	2.4	1
8	Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. European Heart Journal, 2022, 43, 3417-3431.	2.2	50
9	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology </scp> . European Journal of Heart Failure, 2022, 24, 603-619.	7.1	57
10	Heart failure with normal natriuretic peptide levels: more fat, and that is the main problem. European Heart Journal, 2022, 43, 2248-2249.	2.2	2
11	Sex and central obesity in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 1359-1370.	7.1	22
12	Acetazolamide in Decompensated Heart Failure with Volume Overload trial ( <scp>ADVOR</scp> ): baseline characteristics. European Journal of Heart Failure, 2022, 24, 1601-1610.	7.1	18
13	Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea. JAMA Cardiology, 2022, 7, 891.	6.1	43
14	Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 765-772.	7.1	48
15	Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. European Heart Journal, 2021, 42, 1595-1605.	2.2	80
16	New Hemodynamic Insights in Pulmonary Vascular Disease and Heart Failure with Preserved Ejection Fraction. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	0
17	SPOT the DIAGNOSIS. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 240-240.	1.0	O
18	Inpatient Diuretic Management of Acute Heart Failure: A Practical Review. American Journal of Cardiovascular Drugs, 2021, 21, 595-608.	2.2	2

#	Article	IF	CITATIONS
19	Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 954-963.	7.1	24
20	Managing Patients With Short-Term Mechanical Circulatory Support. Journal of the American College of Cardiology, 2021, 77, 1243-1256.	2.8	57
21	MITRAL ANNULAR DYNAMICS IN ATRIAL FIBRILLATION VERSUS SINUS RHYTHM - NOVEL INSIGHTS INTO THE MECHANISM OF ATRIAL FUNCTIONAL MITRAL REGURGITATION. Journal of the American College of Cardiology, 2021, 77, 1733.	2.8	1
22	Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 1648-1658.	7.1	64
23	Iron Deficiency Is Associated With Impaired Biventricular Reserve and Reduced Exercise Capacity in Patients With Unexplained Dyspnea. Journal of Cardiac Failure, 2021, 27, 766-776.	1.7	18
24	Atrial Fibrillation Population Screening. Cardiac Electrophysiology Clinics, 2021, 13, 531-542.	1.7	3
25	The European Heart Journal Acute Cardiovascular Care (EHJ ACVC) 2022: message from the editorial board. European Heart Journal: Acute Cardiovascular Care, 2021, , .	1.0	0
26	Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction. Open Heart, 2021, 8, e001701.	2.3	7
27	Hyponatraemia in heart failure: time for new solutions?. Heart, 2021, , heartjnl-2021-320277.	2.9	2
28	Renal function in myocardial infarction: does serum creatinine tells the whole story?. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 682-683.	1.0	0
29	The Detrimental Effect of RA Pacing onÂLA Function and Clinical Outcome inÂCardiac Resynchronization Therapy. JACC: Cardiovascular Imaging, 2020, 13, 895-906.	5.3	13
30	Evaluation of kidney function throughout the heart failure trajectory–Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 584-603.	7.1	213
31	Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. Heart, 2020, 106, 845-851.	2.9	3
32	Fulminant macrophage activation syndrome in a patient with anti-synthetase syndrome. Rheumatology, 2020, 59, 1775-1777.	1.9	1
33	Navigating the risks in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 372-374.	1.0	0
34	Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with betaâ€blockers. ESC Heart Failure, 2020, 7, 3049-3058.	3.1	3
35	Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 402-414.	1.9	2
36	Altered Hemodynamics and End-Organ Damage in Heart Failure. Circulation, 2020, 142, 998-1012.	1.6	103

#	Article	IF	Citations
37	Spironolactone: diuretic or diseaseâ€modifying drug in heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2020, 22, 1611-1614.	7.1	2
38	Getting the "Right―Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure. Journal of the American Heart Association, 2020, 9, e017292.	3.7	2
39	Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction. Journal of Cardiovascular Translational Research, 2020, 13, 519-527.	2.4	4
40	LA Mechanics in Decompensated HeartÂFailure. JACC: Cardiovascular Imaging, 2020, 13, 1107-1115.	5.3	40
41	Atrial Dysfunction in Patients WithÂHeartÂFailure With Preserved Ejection FractionÂandÂAtrialÂFibrillation. Journal of the American College of Cardiology, 2020, 76, 1051-1064.	2.8	202
42	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESSâ€HF. Journal of the American Heart Association, 2020, 9, e015752.	3.7	11
43	Diuretic Therapy Complicated by Hyponatremia. , 2020, , 175-189.		0
44	Cause-specific mortality and heart failure readmissions according to the HFA-PEFF algorithm in patients hospitalised for heart failure with preserved ejection fraction. European Heart Journal, 2020, 41, .	2.2	0
45	Atrial fibrillation burden and risk of new development through artificial intelligence analysis of an electrocardiogram in hospitalized patients with heart failure and preserved ejection fraction. European Heart Journal, 2020, 41, .	2.2	1
46	Obesity accelerates cardiac senescence in heart failure with preserved ejection fraction. European Heart Journal, 2020, 41, .	2.2	0
47	Abstract 14283: Coronary Microvascular Function is Correlated With Peak Exercise Capacity in Patients With Unexplained Cardiac Exertion Symptoms and Non-obstructive Coronary Artery Disease. Circulation, 2020, 142, .	1.6	0
48	Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction. Journal of Cardiac Failure, 2019, 25, S31.	1.7	0
49	Predicting Early Mortality Among Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2019, 25, 812-818.	1.7	2
50	Acetazolamide to Increase Natriuresis in Congestive Heart Failure at High Risk for Diuretic Resistance. Journal of Cardiac Failure, 2019, 25, S81.	1.7	0
51	Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. European Journal of Heart Failure, 2019, 21, 1415-1422.	7.1	70
52	Urinary Sodium Profiling in Chronic HeartÂFailure to Detect Development of Acute Decompensated Heart Failure. JACC: Heart Failure, 2019, 7, 404-414.	4.1	42
53	Atrial Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 2465-2476.	2.8	218
54	Atrial fibrillation screening with photo-plethysmography through a smartphone camera. Europace, 2019, 21, 1167-1175.	1.7	44

#	Article	IF	Citations
55	Utility of Urine Biomarkers and Electrolytes for the Management of Heart Failure. Current Heart Failure Reports, 2019, 16, 240-249.	3.3	12
56	Salt sensitivity: When do we get too much of a good thing?. European Journal of Preventive Cardiology, 2019, 26, 950-951.	1.8	0
57	Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiologica, 2019, 74, 100-107.	0.9	21
58	Mobile Phone–Based Use of the Photoplethysmography Technique to Detect Atrial Fibrillation in Primary Care: Diagnostic Accuracy Study of the FibriCheck App. JMIR MHealth and UHealth, 2019, 7, e12284.	3.7	82
59	Protocol-driven remote monitoring of cardiac resynchronization therapy as part of a heart failure disease management strategy. Acta Cardiologica, 2018, 73, 230-239.	0.9	2
60	Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low. Acta Cardiologica, 2018, 73, 335-341.	0.9	11
61	Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiologica, 2018, 73, 115-123.	0.9	122
62	Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. Heart Rhythm, 2018, 15, 130-136.	0.7	15
63	Diuretics in cardiorenal syndrome: what's new?. Intensive Care Medicine, 2018, 44, 359-362.	8.2	4
64	Value of routine investigations to predict loop diuretic down-titration success in stable heart failure. International Journal of Cardiology, 2018, 250, 171-175.	1.7	17
65	Editor's Choice- What do small serum creatinine changes tell us about outcomes after acute myocardial infarction?. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 739-742.	1.0	13
66	Limited contractile reserve contributes to poor peak exercise capacity in ironâ€deficient heart failure. European Journal of Heart Failure, 2018, 20, 806-808.	7.1	25
67	Selective abdominal venous congestion induces adverse renal and hepatic morphological and functional alterations despite a preserved cardiac function. Scientific Reports, 2018, 8, 17757.	3.3	26
68	Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume) Tj ETQq0 0 0	rgBT/Ove 7.1	rlo၄န္ဒ 10 Tf 50
69	Effect of Cardiac Resynchronization Therapy on Exercise-Induced Pulmonary Hypertension and Right Ventricular-Arterial Coupling. Circulation: Cardiovascular Imaging, 2018, 11, e007813.	2.6	26
70	Selective abdominal venous congestion to investigate cardiorenal interactions in a rat model. PLoS ONE, 2018, 13, e0197687.	2.5	12
71	Hyponatremia in Acute Heart Failure in Relation to Hematocrit Levels: Clinical Relevance and Prognostic Implication. CardioRenal Medicine, 2018, 8, 259-270.	1.9	7
72	Editor's Choice-Diuretic resistance in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 379-389.	1.0	46

#	Article	IF	Citations
73	Global myocardial oedema in advanced decompensated heart failure. European Heart Journal Cardiovascular Imaging, 2017, 18, 787-794.	1.2	50
74	Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implications. International Journal of Cardiology, 2017, 243, 318-325.	1.7	5
75	Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions. American Journal of Cardiology, 2017, 120, 267-273.	1.6	26
76	Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. European Heart Journal, 2017, 38, 1872-1882.	2.2	126
77	Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2017, 23, 597-605.	1.7	29
78	Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 23.	0.9	69
79	Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator. Heart, 2017, 103, heartjnl-2017-311423.	2.9	9
80	Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. Current Heart Failure Reports, 2017, 14, 275-283.	3.3	15
81	SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys. Current Heart Failure Reports, 2017, 14, 331-337.	3.3	14
82	Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure. Journal of Cardiac Failure, 2017, 23, 138-144.	1.7	17
83	Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 119, 65-70.	1.6	34
84	Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2017, 18, 147032031772991.	1.7	19
85	Bioimpedance Alerts from Cardiovascular Implantable Electronic Devices: Observational Study of Diagnostic Relevance and Clinical Outcomes. Journal of Medical Internet Research, 2017, 19, e393.	4.3	6
86	Subclinical volume overload in stable outpatients with chronic heart failure. Acta Cardiologica, 2016, 71, 299-307.	0.9	1
87	Plasma Renin Activity in Distinct Patient Populations with Heart Failure and Reduced Ejection Fraction. Journal of Cardiac Failure, 2016, 22, S31-S32.	1.7	O
88	Mode of Death in Octogenarians Treated With Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2016, 22, 970-977.	1.7	18
89	Decongestion: more than meets the eye!. European Journal of Heart Failure, 2016, 18, 192-194.	7.1	8
90	Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 177-184.	1.0	9

#	Article	IF	Citations
91	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, e002453.	3.9	61
92	Management of Cardio-Renal Syndrome and Diuretic Resistance. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 11.	0.9	37
93	Transient Hyponatremia During Hospitalization for Acute Heart Failure. American Journal of Medicine, 2016, 129, 620-627.	1.5	19
94	Subclinical volume overload in stable outpatients with chronic heart failure. Acta Cardiologica, 2016, 71, 299-307.	0.9	0
95	Inadequate Heart Rate Control in Ambulatory Patients with Systolic Heart Failure Despite Broad Beta Blocker Utilization: A Single Center Experience. Journal of Cardiac Failure, 2015, 21, S12-S13.	1.7	0
96	Prognostic Implications of Serum Chloride Levels in Patients with Stable Heart Failure. Journal of Cardiac Failure, 2015, 21, S27.	1.7	0
97	Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiologica, 2015, 70, 265-273.	0.9	71
98	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response. Acta Cardiologica, 2015, 70, 565-572.	0.9	3
99	Response and tolerance to oral vasodilator upâ€titration after intravenous vasodilator therapy in advanced decompensated heart failure. European Journal of Heart Failure, 2015, 17, 956-963.	7.1	6
100	Protein carbamylation and cardiovascular disease. Kidney International, 2015, 88, 474-478.	5.2	94
101	Kidney-Organ Interaction., 2015,, 69-85.		1
102	Renin-Angiotensin-Aldosterone System Activation During Decongestion in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 108-111.	4.1	25
103	Mitral Valve Area During Exercise After Restrictive Mitral Valve Annuloplasty. Journal of the American College of Cardiology, 2015, 65, 452-461.	2.8	39
104	The Pathophysiological Role of Interstitial Sodium in Heart Failure. Journal of the American College of Cardiology, 2015, 65, 378-388.	2.8	125
105	Hyponatremia in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2015, 65, 480-492.	2.8	124
106	Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. European Journal of Heart Failure, 2015, 17, 320-328.	7.1	18
107	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	7
108	Hyponatremia Patterns During Hospitalization for Acute Heart Failure. Journal of Cardiac Failure, 2015, 21, S88.	1.7	0

#	Article	IF	CITATIONS
109	The Figureâ€ofâ€Eight Artifact in the Echocardiographic Assessment of Percutaneous Disc Occluders: Impact of Imaging Depth and Device Type. Echocardiography, 2015, 32, 557-564.	0.9	4
110	Optimizing CRT - Do We Need More Leads and Delivery Methods. Journal of Atrial Fibrillation, 2015, 7, 1202.	0.5	0
111	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response. Acta Cardiologica, 2015, 70, 565-72.	0.9	1
112	The kidney in congestive heart failure: †are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'. European Journal of Heart Failure, 2014, 16, 133-142.	7.1	125
113	Asymptomatic episodes of device-registered atrial tachyarrhythmia are not associated with worse cardiac resynchronization therapy response. Europace, 2014, 16, 1197-1204.	1.7	4
114	Management of the Cardiorenal Syndrome in Decompensated Heart Failure. CardioRenal Medicine, 2014, 4, 176-188.	1.9	44
115	Urinary Composition During Decongestive Treatment in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 766-772.	3.9	71
116	New Insights into Combinational Drug Therapy to Manage Congestion in Heart Failure. Current Heart Failure Reports, 2014, 11, 1-9.	3.3	21
117	Tricuspid annuloplasty concomitant with mitral valve surgery: Effects on right ventricular remodeling. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1256-1264.	0.8	49
118	Insufficient Natriuretic Response to Continuous Intravenous Furosemide Is Associated With Poor Long-Term Outcomes in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2014, 20, 392-399.	1.7	120
119	Prognostic Value of Glomerular Filtration Changes Versus Natriuretic Response in Decompensated Heart Failure With Reduced Ejection. Journal of Cardiac Failure, 2014, 20, 817-824.	1.7	17
120	Pulmonary Vascular Response to Exercise in Heart Failure with Reduced Ejection Fraction and Pulmonary Hypertension. Journal of Cardiac Failure, 2014, 20, S4.	1.7	0
121	Natriuretic Response to Diuretic Therapy in Decompensated Heart Failure with Reduced Ejection Fraction and Volume Overload. Journal of Cardiac Failure, 2014, 20, S19-S20.	1.7	0
122	Prognostic Value of Glomerular Filtration Estimates versus Natriuretic Response in Decompensated Heart Failure Patients with Reduced Ejection Fraction Who Achieve Effective Decongestion. Journal of Cardiac Failure, 2014, 20, S20.	1.7	0
123	Insufficient Natriuretic Response to Continuous Intravenous Furosemide Is Associated with Poor Long-Term Outcomes in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2014, 20, S40-S41.	1.7	2
124	Combined management of atrial fibrillation and heart failure: case studies. Heart Failure Reviews, 2014, 19, 331-339.	3.9	1
125	Etiology and Relevance of the Figure-of-Eight Artifact on Echocardiography after Percutaneous Left Atrial Appendage Closure with the Amplatzer Cardiac Plug. Journal of the American Society of Echocardiography, 2014, 27, 323-328.e1.	2.8	12
126	Implementation of transmural disease management in patients admitted with advanced heart failure. Acta Cardiologica, 2014, 69, 145-154.	0.9	5

#	Article	IF	CITATIONS
127	The polycompartment syndrome: a concise state-of-the-art review. Anaesthesiology Intensive Therapy, 2014, 46, 433-450.	1.0	77
128	Abdominal Contributions to Cardiorenal Dysfunction in Congestive Heart Failure. Journal of the American College of Cardiology, 2013, 62, 485-495.	2.8	322
129	Increasing Diuresis in Congestive Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1184-1186.	2.8	3
130	Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy. Europace, 2013, 15, 1747-1756.	1.7	21
131	Novel Urinary Biomarkers in Detecting Acute Kidney Injury, Persistent Renal Impairment, and All-Cause Mortality Following Decongestive Therapy in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2013, 19, 621-628.	1.7	67
132	Clinical Outcomes After Tricuspid Valve Annuloplasty in Addition to Mitral Valve Surgery. Congestive Heart Failure, 2013, 19, 70-76.	2.0	7
133	Novel Urinary Biomarkers in Detecting Worsening Renal Impairment and Mortality Following Decongestive Therapy in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2013, 19, S55.	1.7	0
134	Uptitration of Renin-Angiotensin System Blocker and Beta-Blocker Therapy in Patients Hospitalized for Heart Failure With Reduced Versus Preserved Left Ventricular Ejection Fractions. American Journal of Cardiology, 2013, 112, 1913-1920.	1.6	23
135	Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart, 2013, 99, 314-319.	2.9	16
136	Response to cardiac resynchronization therapy in elderly patients (â%¥70 years) and octogenarians. European Journal of Heart Failure, 2013, 15, 203-210.	7.1	58
137	Cardiac resynchronization therapy with or without defi brillator: experience from a high-volume Belgian implantation centre. Acta Cardiologica, 2013, 68, 37-45.	0.9	5
138	Who should receive calcium and vitamin D supplementation?. Age and Ageing, 2012, 41, 576-580.	1.6	25
139	Comorbidity Significantly Affects Clinical Outcome After Cardiac Resynchronization Therapy Regardless of Ventricular Remodeling. Journal of Cardiac Failure, 2012, 18, 845-853.	1.7	35
140	Lymph node biopsies in a general internal medicine department: algorithm or individualized decision-making?. Acta Clinica Belgica, 2011, 66, 274-9.	1.2	1
141	No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. Cephalalgia, 2010, 30, 1354-1365.	3.9	5
142	Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload., 0,.		1